STOCK TITAN
  1. Home
  2. News
  3. RARE

Ultragenyx Pharmaceutical Inc. - RARE STOCK NEWS

Welcome to our dedicated page for Ultragenyx Pharmaceutical news (Ticker: RARE), a resource for investors and traders seeking the latest updates and insights on Ultragenyx Pharmaceutical stock.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), founded in 2010, is a clinical-stage biotechnology company dedicated to developing and commercializing innovative therapies for the treatment of serious rare and ultra-rare genetic diseases. The company’s core focus is on debilitating metabolic genetic diseases, for which there are high unmet medical needs, and the biology for treatment is well-understood but lacks approved therapies. Ultragenyx's management team brings extensive experience in rare disease therapeutics.

The company’s diverse product portfolio includes approved medicines like Crysvita, Dojolvi, and Mepsevii. Crysvita is designed for the treatment of X-linked hypophosphatemia (XLH), a rare genetic bone disease, and has shown significant growth with revenue reaching $328 million in 2023. Dojolvi targets long-chain fatty acid oxidation disorders and saw a 27% revenue increase in 2023. Mepsevii treats Mucopolysaccharidosis VII, another severe genetic disorder.

Recent Achievements and Financial Performance

In 2023, Ultragenyx reported total revenues of $434 million, a 20% increase from the previous year. The company has a robust pipeline with several candidates in late-stage clinical trials. For instance, the Phase 3 Orbit study for UX143 (setrusumab) in Osteogenesis Imperfecta (OI) completed enrollment and showed promising interim results with a 67% reduction in fracture rates.

Ongoing Projects

  • GTX-102: An antisense oligonucleotide for Angelman syndrome showed significant improvements in clinical trials, with plans for a Phase 3 study in 2024.
  • UX701: A gene therapy for Wilson disease, with data expected in mid-2024.
  • DTX401: A gene therapy for Glycogen Storage Disease Type Ia (GSDIa), achieved its primary endpoint in a Phase 3 study.
  • Setrusumab (UX143): Demonstrated significant fracture rate reduction and bone mineral density improvement in OI patients.

Partnerships and Collaborations

Ultragenyx collaborates with various regulatory bodies and advocacy groups to support patients and ensure high-quality clinical trials. The company’s partnership with Mereo BioPharma on setrusumab exemplifies its collaborative approach to drug development.

Corporate Responsibility

Ultragenyx's 2023 Corporate Responsibility Report highlights its commitment to innovation, patient support, diversity, and environmental sustainability. The company has been recognized with several awards, including the Top Places to Work by the Boston Globe and Healthcare’s Best Companies to Work by U.S. News & World Report.

For more information, visit www.ultragenyx.com.

News

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. grants 12,130 restricted stock units to new non-executive officers under the Employment Inducement Plan. The awards were approved by the compensation committee and vest over four years. The grant is an inducement material to new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
-
News

Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage; Pipeline Updates and 2024 Milestones

Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. (RARE) reported preliminary 2023 total revenue of $430-435 million, with Crysvita revenue of $325-330 million and Dojolvi revenue of $70-71 million. The 2024 expected revenue guidance is between $500-530 million, with Crysvita revenue of $375-400 million and Dojolvi revenue of $75-80 million. The year-end 2023 cash balance was approximately $776 million, and the 2024 guidance for net cash used in operations is expected to be less than $400 million. Ultragenyx expects significant momentum in 2024, with clinical catalysts across multiple value-driving programs, meaningful revenue growth from commercial products, and financial discipline. The company also provided updates on clinical milestones for various gene therapy programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that the National Institute for Health and Care Excellence (NICE) has recommended Evkeeza® (evinacumab) to NHS England. The drug is the first angiopoietin-like 3 (ANGPTL3) inhibitor treatment indicated for adults and adolescent patients aged 12 years and older with homozygous familial hypercholesterolemia (HoFH). NICE acknowledged the clinical and economic benefits of Evkeeza, highlighting its commitment to making the drug broadly available to the HoFH community in the U.S., England and Wales, Canada, Italy, and Germany.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
none
News

Ultragenyx Announces Completion of Enrollment in Global Phase 1/2 Trial of GTX-102 in Pediatric Patients with Angelman Syndrome

Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) completes patient enrollment in Phase 1/2 clinical trial of GTX-102 for the treatment of pediatric patients with Angelman syndrome. The company remains on track to report results in the first half of 2024 from at least 20 expansion cohort patients on therapy for a minimum of 6 months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
clinical trial
-
News

Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that Emil D. Kakkis, M.D., Ph.D., the company's CEO and president, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024. The webcast will be accessible from the company’s website, with a replay available for 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
conferences
-
News

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) grants 30,325 restricted stock units to new non-executive officers under the Ultragenyx Employment Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.3%
Tags
none
News

Andelyn Biosciences Selected by Ultragenyx for Late-Stage Process Performance Qualification (PPQ) Manufacturing of Novel Gene Therapy for Sanfilippo Syndrome

Rhea-AI Summary
Andelyn Biosciences, a cell and gene therapy CDMO, has been selected by Ultragenyx (NASDAQ: RARE) to perform late-stage Process Performance Qualification (PPQ) manufacturing of the company's UX111 gene therapy for the potential treatment of Sanfilippo Syndrome (MPS IIIA), leveraging their extensive experience in AAV technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
-
News

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) receives approval from the European Commission to extend the use of Evkeeza (evinacumab) as a treatment for children aged 5 to 11 years with homozygous familial hypercholesterolemia (HoFH). The approval is based on the results of a Phase 3 open-label study showing a 48% reduction in LDL-C levels in children with HoFH after 24 weeks of treatment. Evkeeza is the first angiopoietin-like 3 (ANGPTL3) inhibitor treatment indicated for children as young as 5 years old to control dangerously high levels of low-density lipoprotein cholesterol (LDL-C) caused by HoFH. The treatment is delivered via 60-minute intravenous infusion once monthly and is now reimbursed and commercially available to prescribe for appropriate patients with HoFH in the U.S., Canada, Italy, and Germany, with early access schemes in Austria and France.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
-
News

Ultragenyx to Participate at Investor Conferences in November

Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced its participation in two upcoming investor conferences, the 6th Annual Evercore ISI HealthCONx on November 28 in Miami and the Piper Sandler 35th Annual Healthcare Conference on November 29 in New York City. The company will host 1x1 meetings at both events, and CEO Emil Kakkis, M.D., Ph.D., will participate in a fireside chat at the Piper Sandler conference. The live and archived webcast of the chat will be accessible from the company’s website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
conferences
News

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) has reported the grant of 22,765 restricted stock units to eight newly hired non-executive officers under the Ultragenyx Employment Inducement Plan. The awards were approved by the compensation committee and vest over four years, with 25% of the shares vesting on each anniversary of the grant date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.55%
Tags
none

FAQ

What is the current stock price of Ultragenyx Pharmaceutical (RARE)?

The current stock price of Ultragenyx Pharmaceutical (RARE) is $44.85 as of January 23, 2025.

What is the market cap of Ultragenyx Pharmaceutical (RARE)?

The market cap of Ultragenyx Pharmaceutical (RARE) is approximately 4.0B.

What is the primary focus of Ultragenyx Pharmaceutical Inc.?

Ultragenyx focuses on developing therapies for serious rare and ultra-rare genetic diseases, especially debilitating metabolic genetic diseases.

What are some key products of Ultragenyx?

Key products include Crysvita for X-linked hypophosphatemia (XLH), Dojolvi for long-chain fatty acid oxidation disorders, and Mepsevii for Mucopolysaccharidosis VII.

What were the financial highlights for Ultragenyx in 2023?

Ultragenyx reported $434 million in total revenues in 2023, marking a 20% growth compared to the previous year.

What recent achievements has Ultragenyx made in clinical trials?

Recent achievements include the Phase 3 Orbit study for UX143 showing significant reduction in fracture rates in Osteogenesis Imperfecta patients.

Who leads Ultragenyx Pharmaceutical Inc.?

Ultragenyx is led by a management team experienced in rare disease therapeutics, with Emil D. Kakkis, M.D., Ph.D., serving as the CEO and President.

What partnerships does Ultragenyx have?

Ultragenyx collaborates with various regulatory bodies and advocacy groups and has a notable partnership with Mereo BioPharma for the development of setrusumab.

What is Ultragenyx's commitment to corporate responsibility?

Ultragenyx is committed to innovation, patient support, diversity, and environmental sustainability, as highlighted in its 2023 Corporate Responsibility Report.

How does Ultragenyx engage with the rare disease community?

Ultragenyx works closely with advocacy groups to support and engage affected individuals and families in the clinical testing process.

What are the future plans for GTX-102?

GTX-102, an antisense oligonucleotide for Angelman syndrome, showed significant improvements in clinical trials, with plans for a Phase 3 study in 2024.

Where can I find more information about Ultragenyx?

You can find more information on Ultragenyx's official website at www.ultragenyx.com.
Stock RARE logo
Ultragenyx Pharmaceutical Inc.

Nasdaq:RARE

RARE Rankings

#1462 Ranked by Market Cap
N/A Ranked by Dividends

RARE Stock Data

3.96B
88.07M
3.62%
97.42%
4.02%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
NOVATO